Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Detecting major neurological disorders via saliva

5

Mar 2026

Detecting major neurological disorders via saliva

A team of Korean researchers has, for the first time in the world, developed a technology capable of enabling early diagnosis of major neurological disorders, including epilepsy, Parkinson's disease, and schizophrenia, using only a small amount of saliva.

New ACS framework links surgeon well-being to patient safety

5

Mar 2026

New ACS framework links surgeon well-being to patient safety

The American College of Surgeons (ACS) has released the first national framework outlining measurable workplace standards for surgeons, aimed at improving surgeon well-being, patient safety, and workforce sustainability. The framework is published in the Journal of the American College of Surgeons (JACS).

Tailoring digital safety to the child’s developmental stage

5

Mar 2026

Tailoring digital safety to the child’s developmental stage

The use of generative artificial intelligence (AI), able to produce text, images and video on demand, has grown exponentially in recent years. While its applications for personal and professional use continue to expand, many have questions about how children might be interacting with this technology.

Youth football accounts for nearly one in five sports-related brain injuries

5

Mar 2026

Youth football accounts for nearly one in five sports-related brain injuries

Youth football accounts for the largest share of sports‑related traumatic brain injuries (TBIs) in children and young adults, nearly one in every five TBIs, according to a preliminary study released March 4, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

Researchers find novel path to treat Rett syndrome

5

Mar 2026

Researchers find novel path to treat Rett syndrome

A team of researchers at Texas Children's Duncan Neurological Research Institute (NRI) and Baylor College of Medicine report in Science Translational Medicine a potential new approach to treat Rett syndrome – offering early promise for a rare neurodevelopmental disorder that currently has no cure.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.